

Literatur zum Artikel

Das maligne Pleuramesotheliom – eine interdisziplinäre Herausforderung

1. Ai J, Stevenson JP (2014) Current issues in malignant pleural mesothelioma evaluation and management. *Oncologist* 19: 975–984
2. Ambrogi V, Mineo D, Gatti A, et al (2009) Symptomatic and quality of life changes after extrapleural pneumonectomy for malignant pleural mesothelioma. *J Surg Oncol* 100: 199–204
3. Bolükbas S, Eberlein M, Fisseler-Eckhoff A, et al (2013) Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections. *Lung Cancer* 81: 241–246
4. Bolükbas S, Eberlein M, Schirren J (2012) Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. *J Thorac Oncol* 7: 900–905
5. Bueno R, Reblando J, Glickman J, et al (2004) Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. *Ann Thorac Surg* 78: 1774–1776
6. Cao C, Tian D, Park J, et al (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. *Lung Cancer* 83: 240–245
7. Carbone M, Ly BH, Dodson RF, et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. *J Cell Physiol* 227: 44–58
8. Carbone M, Yang H (2017) Mesothelioma: recent highlights. *Ann Transl Med* 5: 238
9. Chiriac LR, Barletta JA, Yeap BY, et al (2013) Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. *J Clin Oncol* 31: 4544–4549
10. Ellis P, Davies AM, Evans WK, et al (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. *J Thorac Oncol* 1:591–601
11. Flores RM (2005) The role of PET in the surgical management of malignant pleural mesothelioma. *Lung Cancer* 49 Suppl 1: S27–S32
12. Gueugnon F, Cartron PF, Charrier C, et al (2014) New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells. *Oncotarget* 5: 4504–4515
13. Hasegawa S (2014) Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. *Gen Thorac Cardiovasc Surg* 62: 516–521
14. Hofmann HS, Wiebe K (2010) Zytoreduktive Chirurgie und hypertherme intrathorakale Chemotherapieperfusion. *Chirurg* 81: 557–562
15. Jassem J, Ramlau R, Santoro A, et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. *J Clin Oncol* 26: 1698–1704
16. Krug LM, Pass HI, Rusch VW, et al (2009) Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. *J Clin Oncol* 27: 3007–3013
17. Ladanyi M, Zauderer MG, Krug LM, et al (2012) New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment. *Clin Cancer Res* 18: 4485–4490
18. Lang-Lazdunski L (2014) Surgery for malignant pleural mesothelioma: why, when and what? *Lung Cancer* 84: 103–109
19. Mancuso MR, Neal JW (2017) Novel systemic therapy against malignant pleural mesothelioma. *Transl Lung Cancer Res* 6: 295–314
20. Nakas A, Waller D, Lau K, et al (2012) The new case for cervical mediastinoscopy in selection for radical surgery for malignant pleural mesothelioma. *Eur J Cardiothorac Surg* 42: 72–76
21. Neumann V, Loseke S, Nowak D, et al (2013) Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health. *Dtsch Arztebl Int* 110: 319–326
22. Obasaju CK, Ye Z, Wozniak AJ, et al (2007) Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naive patients with malignant pleural mesothelioma: outcomes of an expanded access program. *Lung Cancer* 55: 187–194
23. Opitz I (2014) Management of malignant pleural mesothelioma – the European experience. *J Thorac Dis* 6 Suppl 2: S238–S252
24. Remon J, Reguart N, Corral J, et al (2015) Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. *Cancer Treat Rev* 41: 27–34
25. Rena O, Casadio C (2012) Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. *Lung Cancer* 77: 151–155
26. Scherpereel A, Astoul P, Baas P, et al (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 35: 479–495
27. Schwartz AM, Rezaei MK (2013) Diagnostic surgical pathology in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 143: e2515–2625
28. Schwartz RM, Watson A, Wolf A, et al (2017) The impact of surgical approach on quality of life for pleural malignant mesothelioma. *Ann Transl Med* 5: 230
29. Sugarbaker DJ (2006) Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. *J Thorac Oncol* 1: 175–176
30. Sugarbaker DJ, Gill RR, Yeap BY, et al (2013) Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. *J Thorac Cardiovasc Surg* 145: 955–963
31. Taioli E, Wolf AS, Flores RM (2015) Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. *Ann Thorac Surg* 99: 472–480
32. Teta MJ, Lau E, Scurman BK, et al (2007) Therapeutic radiation for lymphoma: risk of malignant mesothelioma. *Cancer* 109: 1432–1438
33. Thieke C, Nicolay NH, Sterzing F, et al (2015) Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. *Radiat Oncol* 10: 267
34. Travis WD, Brambilla E, Nicholson AG, et al (2015) The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification. *J Thorac Oncol* 10: 1243–1260
35. Van Meerbeeck JP, Gaafar R, Manegold C, et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 23: 6881–6889
36. Van Schil PE, Opitz I, Weder W, et al (2014) Multimodal management of malignant pleural mesothelioma: where are we today? *Eur Respir J* 44: 754–764
37. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 21: 2636–2644
38. Williams T, Duraid H, Watson S, et al (2015) Extended pleurectomy and decortication for malignant pleural mesothelioma is an effective and safe cytoreductive surgery in the elderly. *Ann Thorac Surg* 100: 1868–1874
39. Zucali PA, Ceresoli GL, Garassino I, et al (2008) Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. *Cancer* 112: 1555–1561